31 results
8-K
EX-99.1
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
that demonstrate the potential to harness the power of EMMs to tackle prevalent chronic conditions and I believe the company is now well positioned
424B5
AXLA
Axcella Health Inc.
13 Oct 22
Prospectus supplement for primary offering
7:55am
outcome measure of fatigue that has been used in measuring subject impact in fatigue states such as chronic fatigue syndrome. The Clinical Trial
8-K
EX-99.2
AXLA
Axcella Health Inc.
29 Sep 22
Regulation FD Disclosure
9:15am
— Decreasing inflammation Axcella’s clinical data demonstrate the potential to harness the power of EMMs to tackle complex chronic conditions — Improving
8-K
636t1lesy34s
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.2
hjjbm
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
g6m6fqug
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
424B5
vy1vz0gx fn
16 Mar 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
hn9 jrrubkh9a64o1kd
10 Jan 22
Other Events
8:00am
8-K
EX-99.2
efrj9
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
424B4
6kh12ny
14 May 20
Prospectus supplement with pricing info
5:15pm